Good news · Health & science · 19 November 2026

NHS England approves first immunotherapy for advanced anal cancer

NHS England has confirmed that retifanlimab, the first immunotherapy approved for advanced anal cancer, is now available to eligible patients. The treatment was fast-tracked for approval and began rollout immediately. It is intended for adults whose cancer has spread locally and cannot be surgically removed.

NHS England has announced that retifanlimab is now available on the NHS for eligible patients with advanced anal cancer. This marks the first time an immunotherapy has been specifically approved for this condition. Professor Peter Johnson, National Clinical Director for Cancer at NHS England, stated: "Access to this life-extending drug is one of the most significant steps in decades for people living with advanced anal cancer - and this treatment can give them precious extra time with their family and loved ones."

Figures published with the announcement show that retifanlimab offers an average additional survival time of 11 months compared to chemotherapy alone. Patients receiving retifanlimab alongside chemotherapy have an average survival length of 32.8 months, whereas those receiving chemotherapy alone have an average survival length of 22.2 months. Approximately 250 patients per year are expected to be eligible for the treatment, out of the 1,600 people diagnosed with anal cancer in the UK each year.

The treatment is administered via a drip once every four weeks for up to one year. It is available to patients whose cancer has spread or returned locally and cannot be surgically removed. The rollout started immediately following NICE approval, with the drug being made available within a week due to fast-tracking efforts. Pete Williams, General Manager UKI & Head of Mid-Size Markets at Incyte Biosciences, said: "We are pleased that retifanlimab has been approved for adults with advanced anal cancer in England."

The approval is limited to adults with advanced anal cancer where the disease has spread or come back locally and is not suitable for surgery. The announcement does not specify further details on side effects or long-term outcomes beyond the survival figures provided.

The original: NHS fast tracks rollout of first ever targeted treatment for anal cancer (NHS England, 12 November 2026)

Written by StreetOwl from NHS England’s own announcement. It was drafted by StreetOwl’s own model, every figure and quotation was checked by code against the announcement, and it was read and approved by Michael Rossi before it went up. It says what was announced, not what anyone should do about it.

More StreetOwl news →

← Back to StreetOwl